Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO. The company sold a plant in Capua, Italy, to German-headquartered industrial outfit Livia, getting rid of a facility that specializes in small molecules and enzymes. Separately, DPx, Patheon's parent company, sold off its agriculture and fine chemicals businesses to Ardian. Meanwhile, Patheon is preparing for a $100 million U.S. IPO. Livia deal | Ardian acquisition

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.